Table 5. Economic evaluation results.
PSA screening | No screening | Difference | |
---|---|---|---|
Screening costs | ¥297,354 | ¥0 | ¥297,354 |
End-of life costs | ¥429,612 | ¥448,669 | −¥19,057 |
PC-related treatment costs | ¥1,201,330 | ¥874,751 | ¥326,579 |
Total costs | ¥1,928,296 | ¥1,323,420 | ¥604,876 |
Total LY | 2,472.39 | 2,446.09 | 26.30 |
Total QALY | 2,452.08 | 2,436.39 | 15.69 |
ICER | – | – | ¥38,550/QALY |
PSA, prostate specific antigen; PC, prostate cancer; LY, life year; QALY, quality-adjusted life year; ICER, incremental cost-effectiveness ratio.